Core Insights - Medtronic is positioned to accelerate revenue and earnings growth through engineering, manufacturing, and regulatory expertise [1][2] - The company is focusing on generational growth drivers and a continuous pipeline of new technologies in various medical fields [1] - Medtronic aims to expand margins to increase R&D investment and enhance EPS leverage [2] - Strategic portfolio management and capital allocation are key components of the company's growth strategy [2]

PresentationWelcome, everyone. I'm Robbie Marcus, the Med Tech Analyst at JPMorgan. Very happy to introduce our next speaker, Bernard Zovighian at Edwards. Bernard is going to do a presentation followed by some Q&A. Bernard?Bernard ZovighianCEO & Director Thank you, Robbie, for hosting. Good morning, everyone. Great to see all of you. I'm very excited to share with you the vision we have for the company in 2026 and beyond. We'll be making some forward-looking statements, which involve risk. They are all lis ...

FRANKLIN LAKES, N.J., Jan. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2026 Annual Meeting of Shareholders (the "Annual Meeting") on Tuesday, January 27, 2026, at 1:00 p.m. (ET). As described in the proxy materials for the Annual Meeting previously distributed, shareholders as of the close of business on December 8, 2025, or their duly authorized proxies, will be able to attend and partic ...

PresentationLife Sciences and Diagnostics team. Pleased to be joined by the management team of Bruker. This is a standard 40-minute session. We'll do a corporate presentation and then Q&A afterwards. Frank, take it away.Frank LaukienChairman, CEO & President Good morning, everybody. Thank you, Casey. Well, good to see many familiar faces. Welcome once again back to San Francisco and the JPMorgan conference. I'll give you an incremental evolutionary presentation today and an update on the key themes for Bruk ...

Core Viewpoint - Haemonetics Corporation is enhancing its market position through strategic acquisitions, specifically the acquisition of Vivasure Medical Limited, which will strengthen its capabilities in blood management solutions and structural heart procedures [1][3][6] Group 1: Company Overview - Haemonetics Corporation specializes in blood management solutions and is recognized for its innovative medical technology products [1] - The company faces competition in the medical technology sector but is actively working to strengthen its position through acquisitions and product development [1] Group 2: Acquisition Details - Haemonetics announced the acquisition of Vivasure Medical Limited for €100 million upfront, with potential milestone payments of up to €85 million [3] - The acquisition will be funded with cash on hand, indicating Haemonetics' financial strength [3][6] - Vivasure's PerQseal Elite system, which is designed for closing large-bore arterial and venous access sites, is a significant addition to Haemonetics' product offerings [4] Group 3: Product Impact - The PerQseal Elite system has received CE Mark approval in Europe and has a Premarket Approval application submitted to the U.S. FDA [5] - The system demonstrated a 0% major complication rate at thirty days in the ELITE arterial study, showcasing its effectiveness and ease of use [5] - This acquisition is expected to enhance Haemonetics' position in the cardiology sector, aligning with the growing demand for large-bore vascular access [4][5] Group 4: Market Performance - Barrington set a price target of $93 for Haemonetics, indicating a potential upside of 13.37% from its current trading price of $82.03 [2][6] - The stock has shown a recent decrease of 2.39%, with a trading range between $81.94 and $84.92 [2] - Over the past year, the stock has fluctuated between $47.32 and $87.32, indicating significant volatility [2]

PresentationOkay. Thanks, everyone, for coming today. My name is Allen Gong, here on the JPMorgan Medtech team. I'm really excited to have the management team of iRhythm here today this morning. We're going to start off with some prepared remarks from CEO, Quentin Blackford, and then we're going to tag in Dan Wilson, CFO, for some Q&A after that. So Quentin, if you could start us off.Quentin BlackfordPresident, CEO & Director Terrific. Can you guys hear me okay? Thanks for having us, Allen. We appreciate th ...

Medtronic 44th Annual J.P. Morgan Healthcare Conference Geoff Martha, Chairman and CEO January 12, 2026 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, qovernment regulation, geopolitical conflicts, ch ...

Johnson & Johnson (NYSE:JNJ) FY Conference January 12, 2026 11:15 AM ET Company ParticipantsJoaquin Duato - Chairman and CEOChris Schott - Managing Director and Senior Equity Research AnalysChris SchottGood morning. I'm Chris Schott from JPMorgan, and it's my pleasure to be hosting this fireside discussion with Joaquin Duato, the Chairman and CEO of J&J. Joaquin, happy New Year.Joaquin DuatoThank you.Chris SchottGreat speaking with you today. Do you want to just open up the conversation? We're coming off of ...

iRhythm Technologies (NasdaqGS:IRTC) FY Conference January 12, 2026 11:15 AM ET Company ParticipantsQuentin Blackford - President and CEODan Wilson - CFOConference Call ParticipantsAllen Gong - VP and Equity Research AnalystAllen GongOkay, thanks everyone for coming today. My name's Allen Gong here on the JPMorgan MedTech team. I'm really excited to have the management team of iRhythm here today this morning. We're going to start off with some prepared remarks from CEO Quentin Blackford, and then we're goin ...

MESA, AZ / ACCESS Newswire / January 12, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), a technology-focused company developing AI-driven consumer, wellness, and medical applications, today provided its 2026 annual shareholder update outlining its short-term, near-term, and long-term strategic goals as the Company advances its next phase of growth. These updates are also updated on our corporate website www.medicalcaretechnologies.com. ...